Background
Methods
Subjects and study design
Measurements
Statistical analysis
Results
Baseline characteristics and medications
Sevelamer (n = 23) | Calcium Carbonate (n = 27) |
P
| |
---|---|---|---|
Age (yr) | 59.61 ± 8.16 | 56.96 ± 7.72 | 0.248 |
Gender (male) | 11 (47.83 %) | 18 (66.67 %) | 0.149 |
Hemodialysis (yr) | 7.00 (5) | 5.00 (4) | 0.313 |
DM (no) | 9 (39.13 %) | 8 (29.63 %) | 0.557 |
Use of vitamin D (no) | 9 (39.13 %) | 13 (48.14 %) | 0.577 |
Use of vitamin D (months) | 77 | 81 | 0.775 |
LCB (no) | 7 (30.43 %) | 6 (22.22 %) | 0.537 |
Statin (no) | 7 (30.43 %) | 5 (18.52 %) | 0.305 |
Anti-hypertension drug (no) | 16 (69.56 %) | 20 (74.07 %) | 0.761 |
Ca (mg/dL) | 9.37 ± 0.66 | 9.37 ± 0.73 | 0.986 |
P (mg/dL) | 6.54 ± 0.91 | 7.22 ± 0.98 | 0.015* |
iPTH (pg/mL) | 354.70 (332.70) | 320.90 (371.8) | 0.633 |
ALK-P (IU/L) | 82.17 ± 32.71 | 65.67 ± 23.70 | 0.061 |
HsCRP (mg/L) | 2.3 (5.8) | 3.10 (6.1) | 0.697 |
Hct (%) | 33.10 ± 3.87 | 32.49 ± 3.11 | 0.549 |
Albumin (g/L) | 39.92 ± 3.13 | 39.81 ± 2.86 | 0.866 |
TG (mg/dL) | 98.00 (86.00) | 113.00 (127.00) | 0.459 |
LDL-C (mg/dL) | 108.96 ± 30.10 | 112.93 ± 33.46 | 0.661 |
Fetuin-A (ug/mL) | 210.61 (104.73) | 203.95 (107.87) | 0.961 |
Fetuin-A: Coefficient ρ (P) | |
---|---|
Age (yr) | −0.209 (0.145) |
HD duration (yr) | −0.324 (0.022*) |
DM or not | −0.116 (0.424) |
Ca | 0.100 (0.491) |
P | −0.016 (0.915) |
iPTH | 0.105 (0.467) |
ALK-P | −0.40 (0.783) |
HsCRP | −0.135 (0.349) |
Albumin | 0.341 (0.015*) |
LDL-C | 0.111 (0.443) |
TG | −0.011 (0.937) |
Comparison of serum fetuin-A level and other parameters before and after 48-week treatment
Sevelamer (n = 23) | Calcium Carbonate (n = 27) | |||||
---|---|---|---|---|---|---|
BT | AT |
P
| BT | AT |
P
| |
Ca (mg/dL) | 9.37 ± 0.66 | 9.63 ± 0.80 | 0.038* | 9.37 ± 0.73 | 10.17 ± 0.90 | 0.000* |
P (mg/dL) | 6.54 ± 0.91 | 5.07 ± 0.85 | 0.000* | 7.22 ± 0.98 | 5.70 ± 1.01 | 0.000* |
iPTH (pg/mL) | 354.70 (332.70) | 329.60 (319.80) | 0.903 | 320.90 (371.8) | 165.20 (405.60) | 0.001* |
ALK-P (IU/L) | 82.17 ± 32.71 | 112.43 ± 43.21 | 0.004* | 65.67 ± 23.70 | 64.41 ± 23.13 | 0.609 |
HsCRP (mg/L) | 2.3 (5.8) | 1.6 (3.1) | 0.003* | 3.10 (6.1) | 1.9 (6.6) | 0.866 |
Hct (%) | 33.10 ± 3.87 | 32.80 ± 3.72 | 0.728 | 32.49 ± 3.11 | 32.49 ± 4.58 | 0.996 |
Albumin (g/L) | 39.92 ± 3.13 | 39.96 ± 3.02 | 1.000 | 39.81 ± 2.86 | 40.78 ± 2.95 | 0.062 |
TG (mg/dL) | 98.00 (86.00) | 96.00 (103) | 0.891 | 113.00 (127.00) | 103.00 (65) | 0.343 |
LDL-C (mg/dL) | 108.96 ± 30.10 | 63.91 ± 20.55 | 0.000* | 112.93 ± 33.46 | 105.19 ± 30.93 | 0.157 |
Fetuin-A (ug/mL) | 210.61 (104.73) | 153.85 (38.64) | 0.003* | 203.95 (107.87) | 170.90 (58.02) | 0.002* |
Comparison of changes in serum fetuin-A and other parameters after 48-week treatment between two groups
Sevelamer (n = 23) | Calcium Carbonate (n = 27) |
P
| |
---|---|---|---|
Δ Ca (mg/dL) | 0.26 ± 0.55 | 0.80 ± 0.93 | 0.015* |
Δ P (mg/dL) | −1.47 ± 0.98 | −1.53 ± 1.27 | 0.871 |
Δ iPTH (pg/mL) | 12.10 (216.60) | −137.10 (255.70) | 0.026* |
Δ ALK-P (IU/L) | 30.26 ± 45.78 | −2.26 ± 22.69 | 0.004* |
Δ HsCRP (mg/L) | −0.9 (2.7) | 0.1 (3.8) | 0.025* |
Δ Hct (%) | −0.30 ± 4.00 | −0.00 ± 3.39 | 0.785 |
Δ Albumin (g/L) | 0.00 ± 2.72 | 0.82 ± 2.31 | 0.241 |
Δ TG (mg/dL) | −11.00 (70) | −13.00 (93) | 0.346 |
Δ LDL-C (mg/dL) | −45.04 ± 28.31 | −7.74 ± 27.59 | 0.000* |
Δ Fetuin-A (ug/mL) | −49.44 (113.78) | −38.21 (78.51) | 0.345 |
Correlations of the changes in serum fetuin-A and related parameters
Fetuin-A: Coefficient ρ (P) | |
---|---|
Sevelamer or not | −0.135 (0.350) |
Vitamin D or not | 0.017 (0.908) |
LCB or not | 0.115 (0.425) |
Δ Ca | −0.230 (0.040*) |
Δ P | −0.091 (0.531) |
Δ iPTH | 0.306 (0.031*) |
Δ ALK-P | 0.145 (0.314) |
Δ hsCRP | −0.085 (0.558) |
Δ Albumin | 0.408 (0.003*) |
Δ TG | −0.113 (0.434) |
Δ LDL-C | 0.132 (0.363) |